Objectives: - Investigate dupilumab's role in keloid treatment.
- Examine its modulation of IL-4 and IL-13 pathways.
- Assess the efficacy and safety of dupilumab through case reviews.
- Analyze varying treatment outcomes.
- Enhance decision-making in keloid management based on patient-specific factors.
- Understand the complex nature of keloid pathophysiology.
Introduction: Keloid scars, characterized by excessive collagen deposition from abnormal wound healing, present significant cosmetic and functional challenges. Traditional treatments, such as intralesional steroids and surgical excision, often yield limited results. Dupilumab, a cutting-edge IL-4 and IL-13 pathway inhibitor, has emerged as a novel therapeutic option. Initial case studies reveal promising outcomes, though variability in results highlights the need for further research to fully determine its effectiveness and refine its role in keloid management.
Materials / method: This review investigates the potential of dupilumab in treating keloid scarring through an extensive literature search. We explored PubMed, MEDLINE, and Embase using targeted Medical Subject Headings and keywords related to dupilumab and keloids. The search focused on recent, peer-reviewed articles, clinical trials, and reviews. We meticulously selected studies based on relevance, and rigorously extracted and synthesized data to evaluate dupilumab’s efficacy and safety in addressing keloid scarring.
Results: Keloids, characterized by excessive scarring from abnormal healing, remain challenging to treat due to their high recurrence rates. While traditional methods like steroids and surgical excision often fall short, dupilumab, targeting IL-4 and IL-13, has shown promise in reducing keloid size and symptoms, particularly in patients with coexisting atopic dermatitis. However, responses varied, with some patients improving significantly while others saw minimal or no benefit. These results highlight the importance of further exploration to optimize therapeutic approaches and enhance outcomes.
Conclusion: Dupilumab, targeting IL-4 and IL-13 signaling, emerges as a promising adjunct in managing keloid scarring, especially for cases resistant to traditional therapies. While some patients have shown notable improvements in keloid size and symptoms, variability in outcomes and limited long-term data necessitate cautious optimism. Personalized treatment plans and ongoing research are crucial to optimize dupilumab's role in keloid therapy, address potential biases, and establish its efficacy and safety profile comprehensively.
利益冲突声明
您有否接受任何资金来支持研究这个主题？
否
您是否接受过关于这项研究的任何酬金或其他报酬？
否
你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否
你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。
